Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients
Ist Teil von
Journal of neuro-oncology, 2011-12, Vol.105 (3), p.591-600
Ort / Verlag
Boston: Springer US
Erscheinungsjahr
2011
Quelle
MEDLINE
Beschreibungen/Notizen
Mutations in the gene encoding isocitrate dehydrogenase enzyme isoforms 1 (
IDH1
) and 2 (
IDH2
) have recently been identified in a large proportion of glial tumors of the CNS, but their mechanistic role in tumor development remains unclear. Here, we assessed the actual impact of
IDH1
and
IDH2
mutations in patients harboring WHO grade II and III gliomas. We sequenced
IDH1
at codon 132 and
IDH2
at codon 172 in 33 patients with WHO grade II and III gliomas who benefited from a preoperative
18
F-FDG positron emission tomography (PET). Immunohistochemical expression of Hypoxia Inducible Factor-1alpha (HIF-1α), Carbonic Anhydrase IX (CAIX), Glucose Transporter 1 (GLUT1) and Caspase 3 active form (CASP3) along with the
R132HIDH1
mutation was assessed in all cases as well as 1p/19q deletion status and p53 expression. HIF-1α expression was found in 15% of
IDH
-mutated compared to 7.7% of
IDH
-nonmutated tumors (
P
= 0.954). Also, GLUT-1 positive staining was found in 5% of
IDH
-mutated and in 7.1% of
IDH
-nonmutated tumors (
P
= 0.794). Finally, CA-IX expression was found in 15% of
IDH
-mutated and in 7.7% of
IDH
-nonmutated tumors (
P
= 0.484). The combined expression of these three hypoxic markers was found in two WHO grade III tumors, one of which was
IDH
-mutated whereas the other was
IDH
-nonmutated (
P
= 0.794). In
IDH
-mutated tumors, the median SUVmax ratio was 2.24 versus 2.15 in
IDH
-nonmutated tumors (
P
= 0.775). Together, these data question the actual relationship between
IDH
mutation status and in vivo hypoxic biomarkers expression in WHO grade II and III gliomas.